North America accounted for a major share of the global idiopathic pulmonary fibrosis treatment market in 2022. Factors bolstering the market growth include the increasing incidence of idiopathic pulmonary fibrosis and technological advancements in this therapeutic segment. Additionally, product launches and strategic initiatives by key market players significantly contribute to the expansion of the idiopathic pulmonary fibrosis treatment market size in North America. With the growing number of research and development activities to treat idiopathic pulmonary fibrosis, improved drugs are being introduced into the market, which results in better access to medicines for a wider patient pool. Further, extensive FDA approvals in the region encourage companies to launch technologically sophisticated products. Asia Pacific is expected to register the fastest CAGR in the global idiopathic pulmonary fibrosis treatment market during 2022–2030. The market growth in the region is ascribed to the acceptance and adoption of cutting-edge technologies that help produce accurate results in healthcare services in significantly shorter spans Healthcare of medical professionals.
Based on drug type, the idiopathic pulmonary fibrosis treatment market is segmented into nintedanib, pirfenidone, and others. The nintedanib segment held a larger market share in 2022. The others segment is anticipated to register a higher CAGR of 46.3% during 2022–2030. Pirfenidone and nintedanib are the popular medicines prescribed to treat fibrotic diseases.
By distribution channel, the global idiopathic pulmonary fibrosis treatment market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest market share in 2022. The online pharmacies segment is anticipated to register the highest CAGR of 17.4% during 2022–2030.
Increasing Number of People Smoking Cigarettes Fuels Idiopathic Pulmonary Fibrosis Treatment Market Growth
Cigarette smoking is one of the well-known risk factors for the development of idiopathic pulmonary fibrosis. Recent studies suggest that smoking may have a detrimental effect on the survival of patients with idiopathic pulmonary fibrosis treatment. Several studies have produced evidence suggesting that increased oxidative stress may promote disease progression in idiopathic pulmonary fibrosis patients who are current and former smokers.
Cigarette smoke contains particulate matter, highly toxic reactive oxygen and nitrogen species (RONS), and other chemicals. These constituents trigger swelling in the body and thus lead to various diseases, including pulmonary fibrosis and cancer. According to the Centers for Disease Control and Prevention (CDC) updates released in May 2023, approximately 12 out of 100 adults (~11.5% of the population) aged 18 and older in the US smoke cigarettes, totaling 28.3 million adult smokers in the US. Therefore, an upsurge in the number of people smoking cigarettes is expected to drive the growth of the idiopathic pulmonary fibrosis treatment market.
Idiopathic Pulmonary Fibrosis Treatment Market: Treatment Overview
Based on drug type, the idiopathic pulmonary fibrosis treatment market is segmented into nintedanib, pirfenidone, and others. The nintedanib segment held a larger market share in 2022. The others segment is anticipated to register a higher CAGR of 46.3% during 2022–2030. Pirfenidone and nintedanib are the popular medicines prescribed to treat fibrotic diseases.
Idiopathic Pulmonary Fibrosis Treatment Market: Competitive Landscape and Key Developments
Genentech, Inc. and Boehringer Ingelheim International GmbH are a few of the key companies operating in the idiopathic pulmonary fibrosis treatment market. Leading players are implementing strategies such as the expansion and diversification of their market presence, the launch of new products, and the acquisition of a new customer base for tapping prevailing business opportunities.
- In May 2023, Cumberland Pharmaceuticals Inc. announced receiving FDA approval for its Investigational New Drug Application (IND) for a Phase II clinical trial focused on patients suffering from idiopathic pulmonary fibrosis, the predominant form of progressive fibrosing lung disease. This approval represents a critical step forward in the advancement of potential treatments for idiopathic pulmonary fibrosis and gives hope to those affected by this challenging disease.
- In October 2022, Boehringer Ingelheim enrolled the first US patient in the FIBRONEER-IPF Phase III study evaluating BI 1015550. BI 1015550 is an experimental phosphodiesterase 4B (PDE4B) inhibitor discovered for treating individuals suffering from idiopathic pulmonary fibrosis. The study is a part of the global FIBRONEER program, which includes two Phase III studies: FIBRONEER-IPF in patients with idiopathic pulmonary fibrosis and FIBRONEER-ILD in adults with other progressive fibrosing interstitial lung diseases (ILDs).
- In June 2022, Accord Healthcare, Inc. announced the addition of pirfenidone to its solid oral product portfolio. This new drug is approved for the treatment of idiopathic pulmonary fibrosis, as it is therapeutically equivalent to Genentech’s Esbriet.
- In May 2022, Sandoz launched its generic pirfenidone, the first AB-rated (fully substitutable) equivalent to Genentech’s Esbriet, for the treatment of patients with idiopathic pulmonary fibrosis. This oral medication was made available for eligible patients through specialty pharmacies with a $0 copay program.
- In March 2022, Bristol Myers Squibb, a leading pharmaceutical company, announced the acquisition of Turning Point Therapeutics, Inc. for US$ 76.00 per share through a definitive merger agreement. This acquisition has significantly strengthened Bristol Myers Squibb’s global presence in the pharmaceutical market, allowing it to be more proactive in bringing innovations to the industry while expanding its portfolio of life-saving therapies and treatments.
- In June 2021, Genentech, a member of the Roche Group, was granted a priority review FOR Esbriet (pirfenidone) after it submitted a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA).